SCHEMBL63410

SCHEMBL63410

Cn1cc(C(=O)NC23CCC(CC2)Cn2c3nc(C(=O)NCc3ccc(F)cc3)c(O)c2=O)cn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.53
KCNH2 Q12809 1/20 0.44
CYP2C9 P11712 1/20 0.44
KCNE1 P15382 1/20 0.38
CCR1 P32246 1/20 0.38
KCNQ1 P51787 1/20 0.38
LMNA P02545 1/20 0.37
HPGD P15428 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
FSCN1 Q16658 1/20 0.37
ERCC1 P07992 1/20 0.36
FEN1 P39748 1/20 0.36
ERCC4 Q92889 1/20 0.36
MAPK1 P28482 1/20 0.36
LIPG Q9Y5X9 1/20 0.35
KIT P10721 1/20 0.35
SCD O00767 1/20 0.35
PLA2G7 Q13093 1/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL52562 0.88 KCNH2 (0.45) SMN1; SMN2KCNH2CYP2C9KCNE1CCR1
SCHEMBL52520 0.87 L3MBTL1 (0.47) SMN1; SMN2KCNH2CYP2C9KCNE1CCR1
SCHEMBL52470 0.87 KCNH2 (0.49) SMN1; SMN2KCNH2CYP2C9KCNE1CCR1
SCHEMBL62584 0.87 KCNH2 (0.45) SMN1; SMN2KCNH2CYP2C9KCNE1CCR1
SCHEMBL52473 0.87 KCNH2 (0.43) SMN1; SMN2KCNH2CYP2C9HPGDERCC1
SCHEMBL418372 0.86 KCNH2 (0.47) SMN1; SMN2KCNH2CYP2C9KCNE1CCR1
SCHEMBL63407 0.86 CYP2C9 (0.46) SMN1; SMN2KCNH2CYP2C9KCNE1CCR1
SCHEMBL63360 0.86 KCNH2 (0.44) SMN1; SMN2KCNH2CYP2C9KCNE1CCR1
SCHEMBL63744 0.86 KCNH2 (0.45) SMN1; SMN2KCNH2CYP2C9KCNE1CCR1
SCHEMBL64238 0.86 KCNH2 (0.44) SMN1; SMN2KCNH2CYP2C9KCNE1CCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253677-A1 HIV Integrase Inhibitors DNTT, POLB, UNG SMN1; SMN2 4431/4885KCNH2 3969/4885CYP2C9 602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.